Littley M D, Hutchings A, Spragg B P, Routledge P A, Lazarus J H
Department of Medicine, Llandough Hospital, South Glamorgan.
Br J Clin Pharmacol. 1988 Jul;26(1):103-6. doi: 10.1111/j.1365-2125.1988.tb03372.x.
Isoniazid acetylation was assessed in 10 thyrotoxic patients before and after standard antithyroid therapy. The group contained five fast and five slow acetylators and all remained within the same phenotypic classification when rendered euthyroid. There was no significant change in the elimination half-life of isoniazid between thyrotoxicosis and euthyroidism for the group as a whole or for fast and slow acetylators considered separately. Thyrotoxicosis does not appear to be an important determinant of isoniazid acetylation in man.
在10例甲状腺毒症患者接受标准抗甲状腺治疗前后，对异烟肼乙酰化情况进行了评估。该组包括5名快乙酰化者和5名慢乙酰化者，在甲状腺功能恢复正常后，所有患者仍处于相同的表型分类。总体而言，无论是甲状腺毒症期还是甲状腺功能正常期，该组患者以及分别考虑的快乙酰化者和慢乙酰化者的异烟肼消除半衰期均无显著变化。甲状腺毒症似乎不是人类异烟肼乙酰化的重要决定因素。
